HAEGTFTSDVS

HAEGTFTSDVS is a synthetic peptide corresponding to the N-terminal fragment of the human glucagon-like peptide-1 (GLP-1) sequence, a key incretin hormone involved in glucose metabolism and pancreatic function. As a biologically relevant peptide, HAEGTFTSDVS is widely utilized in the study of peptide-receptor interactions, signal transduction pathways, and the structural determinants of peptide hormone activity. Its defined sequence and well-characterized properties make it a valuable tool for researchers investigating peptide structure-function relationships, receptor binding affinities, and the molecular mechanisms underlying peptide-mediated signaling in various biological systems.

Peptide-receptor interaction studies: HAEGTFTSDVS is frequently employed in research focused on elucidating the binding dynamics between GLP-1-derived peptides and their cognate receptors, such as the GLP-1 receptor (GLP-1R). By serving as a model peptide, it enables detailed analysis of the molecular determinants governing ligand recognition, receptor activation, and downstream signaling events. These studies provide insight into the specificity and affinity of peptide-receptor interactions, informing the design of novel peptide analogs with tailored biological properties.

Structure-activity relationship (SAR) investigations: The defined sequence of HAEGTFTSDVS allows for systematic exploration of structure-activity relationships within the GLP-1 family of peptides. Researchers can use this peptide as a template for introducing targeted modifications, substitutions, or truncations to assess how specific amino acid residues influence receptor binding and biological activity. Such SAR studies are critical for understanding the functional roles of individual residues and for guiding the rational design of peptide-based research tools or probes.

Peptide synthesis and analytical benchmarking: As a reference standard, HAEGTFTSDVS is valuable in the development and validation of peptide synthesis protocols and analytical methodologies. Its well-characterized sequence makes it an ideal candidate for optimizing solid-phase peptide synthesis techniques, assessing peptide purity, and calibrating chromatographic or mass spectrometric assays. Analytical laboratories and peptide manufacturers benefit from using this peptide to ensure reproducibility and reliability in peptide production workflows.

Biochemical assay development: The peptide is instrumental in the creation and optimization of biochemical assays designed to monitor peptide-mediated signaling, receptor binding, or enzymatic cleavage. HAEGTFTSDVS can be incorporated into in vitro assay systems to evaluate the specificity and sensitivity of detection methods, to quantify receptor-ligand interactions, or to screen for modulators of peptide activity. Its use in assay development contributes to the advancement of high-throughput screening platforms and the identification of novel bioactive compounds.

Pharmacological research models: In preclinical research, HAEGTFTSDVS serves as a model peptide for dissecting the pharmacological properties of GLP-1-related sequences. By studying its interaction with biological targets in cell-based or biochemical systems, scientists can investigate mechanisms of receptor activation, signal transduction, and peptide degradation. These experiments provide foundational knowledge for understanding the broader physiological roles of GLP-1 peptides and for supporting the development of next-generation peptide research tools.

1. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists

2. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs

3. Emu oil in combination with other active ingredients for treating skin imperfections

4. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

5. The spatiotemporal control of signalling and trafficking of the GLP-1R